A widely prescribed class of blood-pressure drugs has been linked to a higher risk of serious kidney problems in people with type 2 diabetes, according to a large observational study — but the researchers are clear that it cannot prove the drugs are to blame.
The analysis examined health data from 31,031 adults with type 2 diabetes between 2016 and 2021. Those taking dihydropyridine calcium-channel blockers (DCCBs) — a common blood-pressure medication — had a 33% greater risk of a major adverse kidney event (hazard ratio 1.33) compared with patients on other blood-pressure drugs. All participants were also on RAS inhibitors and SGLT2 inhibitors, and were followed for a median of 3.5 years. The findings were presented at the European Renal Association (ERA) Congress.
Association, not proof
This is crucial: the study is observational, so it can reveal a link but not causation. The authors state plainly that it “cannot show that DCCBs directly caused the poorer kidney outcomes” and call for prospective studies and randomized trials to confirm. Patients on these drugs often differ in ways that independently affect kidney health.
Why it matters
“Major adverse kidney events” here meant a large loss of kidney function (a 40%+ drop in eGFR) or progression to end-stage kidney disease needing dialysis or transplant — serious outcomes for people with diabetes, who already face elevated kidney risk. The signal is worth studying, but it is not a reason to stop any medication. This article summarizes research presented at a conference and is not medical advice; do not change medications without consulting your doctor.